Coronary artery diseases (CAD) are influenced by multiple genes of modest effect as the methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism, related to MTHFR activity and total plasma homocysteine (tHcy) concentration. This study was designed to evaluate tHcy, oxidized low-density lipoprotein (LDL) (ox-LDL), high-sensibility C-reactive protein (Hs CRP) levels, and homocysteine thiolactonase (HTase) activities as new risk factors for CAD and to investigate an association between MTHFR polymorphism tHcy concentrations and coronary syndrome severity. Our results showed significantly higher levels of tHcy and ox-LDL in patients associated with lower HTase activities. These levels increased proportionally to disease severity. Total plasma Hcy levels were negatively correlated to HTase activities in patients where the TT genotype was significantly more frequent. In a multivariate analysis, tHcy level was the only independent factor affecting the coronary syndrome severity. High tHcy levels are associated with coronary syndrome severity and may be explained either by the elevated prevalence of TT genotype or by the diminished HTase activities.
Boushey CJ, Beresford SAA, Omenn GS, Motulsky AGA quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995;274(13):1049-1057.
2.
Clarke R., Daly L., Robinson K., et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991; 324(17):1149-1155.
3.
Kang S-S., Zhou J., Wong PWK, Kowalisyn J., Strokosch G.Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet. 1988;43(4): 414-421.
4.
Frosst P., Blom HJ, Milos R., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet . 1995;10(1):111-113.
5.
Engbersen AMT , Franken DG, Boers GHJ, Stevens EMB, Trijbels JMF, Blom HJThermolabile 5,10-methylenetetrahydro folate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet. 1995;56(1):142-150.
6.
Kang S-S., Passen EL, Ruggie N., Wong PWK, Sora H.Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease. Circulation. 1993;88(4 pt 1):1463-1469.
7.
Jakubowski H.Biochemical basis of homocysteine toxicity in humans. Mol Cell Life Sci. 2004;61(4):470-487.
8.
Jakubowski H.Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J. 1999;13(15):2277-2283.
9.
Nishi K., Itabe H., Uno M., et al. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol. 2002;22(10):1649-1654.
10.
Ehara S., Ueda M., Naruko T., et al. Elevated levels of low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation . 2001;103(15):1955-1960.
11.
Koubaa N., Hammami S., Nakbi A., et al. Relationship between thiolactonase activity and hyperhomocysteinemia according to MTHFR gene polymorphism in Tunisian Behçet’s disease patients. Clin Chem Lab Med. 2008;46(2):187-192.
12.
Smaoui M., Hammami S., Chaaba R., et al. Lipids and lipoprotein (a) concentration in Tunisian type 2 diabetic patients relationship to glycaemic control and coronary heart disease . J Diabetes Complication. 2004;18:258-263.
13.
Koubaa N., Nakbi A., Smaoui M., et al. Hyperhomocysteinemia and elevated ox-LDL in Tunisian type 2 diabetic patients: role of genetic and dietary factors. Clin Biochem. 2007;40(13-14):1007-1014.
14.
Meleady R., Ueland PM, Blom H., et al. Thermolabile methylenetetrahydrofolate reductase, homocysteine, and cardiovascular disease risk: the European Concerted Action Project. Am J Clin Nutr. 2003;77(1):63-70.
15.
Ilhan N., Kucuksu M., Kaman D., Ilhan N., Ozbay Y.The 677 C/T MTHFR polymorphism is associated with essential hypertension, coronary artery disease, and higher homocysteine levels. Arch Med Res. 2008;39(5):125-130.
16.
Outinen PA, Sood SK, Liaw PC, et al. Characterization of the stress-inducing effects of homocysteine . Biochem J. 1998; 332(pt 1):213-221.
17.
Upchurch GR Jr, Welch GN, Fabian AJ, et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase . J Biol Chem. 1997;272(27):17012-17017.
18.
Refsum H., Ueland PMRecent data are not in conflict with homocysteine as a cardiovascular risk factor. Curr Opin Lipidol. 1998; 9(6):533-539.
19.
Williams KJ , Tabas I.The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 1995;15(5): 551-561.
20.
Hurt-Camejo E. , Olsson U., Wiklund O., Bondjers G., Camejo G.Cellular consequences of the association of apoB lipoproteins with proteoglycans. Potential contribution to atherogenesis . Arterioscler Thromb Vasc Biol. 1997;17(6):1011-1017.
21.
Sniderman AD , Pedersen T., Kjekshus J.Putting low-density lipoproteins at center stage in atherogenesis. Am J Cardiol. 1997 ; 79(1):64-67.
22.
Boers GHJ , Smals AGH , Trijbels JMF , et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med. 1985;313(12):709-715.
23.
Arnesen E., Refsum H., Bonaa KH, Ueland PM, Forde OH, Nordrehaug JESerum total homocysteine and coronary heart disease. Int J Epidemiol. 1995;24(4):704-709.
24.
Kang S.-S, Wong PWK, Cook HY, Norusis M., Messer JVProtein-bound homocyst(e)ine: a possible risk factor for coronary artery disease . J Clin Invest. 1986;77(5):1482-1486.
25.
Nygård O., Vollset SE, Refsum H., et al. Total plasma homocysteine and cardiovascular risk profile: the Hordaland Homocysteine Study . JAMA. 1995;274(19):1526-1533.
26.
Selhub J., Jacques PF, Bostom A., et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med. 1995 ;332(5):286-291.
Morita H., Taguchi J., Kurihara H., et al. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation . 1997;95(8):2032-2036.
29.
Jee SH, Beaty TH, Suh I., Yoon Y., Appel LJThe methylenetetrahydrofolate reductase gene is associated with increased cardiovascular risk in Japan, but not in other populations. Atherosclerosis. 2000;153(1):161-168.
30.
Wilcken DE, Wang XL, Sim AS, McCredie RMDistribution in healthy and coronary populations of the methylenetetrahydrofolate reductase (MTHFR) C677T mutation. Arterioscler Thromb Vasc Biol. 1996;16(7):878-882.
31.
Ma J., Stampfer MJ, Henneken CH, et al. Methylenetetrahydrofolate polymorphism, plasma folate, homocysteine, and risk of myocordias infarction in US physicians. Circulation . 1996; 94(10):2410-2416.
32.
Rothenbacher D., Fischer HG, Hoffmeister A., et al. Homocysteine and methylenetetrahydrofolate reductase genotype: association with risk of coronary heart disease and relation to inflammatory, hemostatic, and lipid parameters. Atherosclerosis . 2002;162(1): 193-200.
33.
Zuntar I., Topic E., Vukosavic D., et al. Croatian population data for the C677T polymorphism in methylenetetrahydrofolate reductase: frequencies in healthy and atherosclerotic study groups. Clin Chim Acta. 2003;335(1-2):95-100.
34.
Kalina A., Czeizel AEThe methylenetetrahydrofolate reductase gene polymorphism (C677T) is associated with increased cardiovascular mortality in Hungary. Int J Cardiol. 2004;97(2): 333-334.
35.
Goyette P., Frosst P., Rosenblatt DS, Rozen R.Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype:phenotype correlation in severe méthylénetétrahydrofolate reductase deficiency. Am J Hum Genet. 1995 ;56(5): 1052-1059.
36.
Harker LA, Harlan JM, Ross R.Effect of sulfinpyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons. Circ Res. 1983;53(6):731-739.
